ֱ

MedpageToday

Optimal Adjuvant Chemo and Targeted Therapy for Early Breast Cancer—CDK 4/6 Inhibitors: ASCO Guideline Rapid Recommendation Update

– An ASCO Reading Room selection


This Reading Room is a collaboration between ֱ® and:

Medpage Today
Below is the abstract of the article. or on the link below.

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the . The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients.

In 2020, ASCO published a guideline on the selection of optimal . This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer.

Read an interview about the guideline update here and expert commentary about it here.

Read the full article

Optimal Adjuvant Chemo and Targeted Therapy for Early Breast Cancer—CDK 4/6 Inhibitors: ASCO Guideline Rapid Recommendation Update

Primary Source

Journal of Clinical Oncology

Source Reference:

ASCO Publications Corner

ASCO Publications Corner